造血干细胞移植治疗血管免疫母细胞性T细胞淋巴瘤的临床结局
回顾性分析2007年6月至2017年6月国内八所医院接受造血干细胞移植的19例血管免疫母细胞性T细胞淋巴瘤患者,其中自体移植12例、异基因移植7例。自体移植与异基因移植的3年总生存率分别为56%与57%(P=0.979),3年无进展生存率分别为34%与57%(P=0.451)。作者认为两种移植均是AITL的有效治疗方法。
要点
- 19例AITL患者接受HSCT,自体12例、异基因7例,异基因均为同胞全相合供者。
- 3年总生存率自体组56% vs 异基因组57%(P=0.979),无统计学差异。
- 3年无进展生存率自体组34% vs 异基因组57%(P=0.451),无统计学差异。
核心结论
- auto-HSCT和allo-HSCT均是AITL的有效治疗方法。
- 临床实践中应根据对化疗的敏感性、危险分层及移植时疾病状态等综合因素选择移植方式。
研究设计与样本
- 回顾性分析2007年6月至2017年6月国内八所医院接受HSCT的AITL患者临床资料。
- 共纳入19例患者,男13例、女6例,中位年龄50(32~60)岁;auto-HSCT组12例,allo-HSCT组7例。
- allo-HSCT组供者均为同胞全相合,其中2例为auto-HSCT后复发患者。
主要发现
- auto-HSCT组移植前CR 5例(5/12)、PR 7例(7/12);allo-HSCT组移植前PR 2例(2/7)、PD 3例(3/7)。
- allo-HSCT组发生急性GVHD 3例(Ⅰ度2例、Ⅱ度1例),慢性GVHD 5例(局限型2例、广泛型3例)。
- auto-HSCT组死亡4例(原发病复发死亡3例、出血1例);allo-HSCT组死亡3例(移植相关死亡2例、原发病复发死亡1例)。
- 3年累积OS:auto-HSCT组56%(95%CI 32%~100%) vs allo-HSCT组57%(95%CI 30%~100%)(P=0.979)。
- 3年累积PFS:auto-HSCT组34%(95%CI 14%~85%) vs allo-HSCT组57%(95%CI 30%~100%)(P=0.451)。
临床怎么用
- 作者认为auto-HSCT和allo-HSCT均是AITL的有效治疗方法。
- 作者认为临床实践中应根据对化疗的敏感性、危险分层及移植时疾病状态等综合因素选择移植方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate clinical outcomes of autologous (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for angioimmunoblastic T-cell lymphoma (AITL) . Methods: From June 2007 to June 2017, clinical data of AITL patients who underwent HSCT in eight hospitals were assessed retrospectively. Results: Of 19 patients, 13 male and 6 female with a median age of 50 (32-60) years old, 12 auto-HSCT and 7 allo-HSCT recipients were enrolled in this study, all donors were HLA-identical siblings. Two of allo-HSCT recipients were relapsed auto-HSCT ones. There were 5 patients (5/12) in complete response (CR) status and 7 (7/12) in partial remission (PR) status before transplantation in auto-HSCT group, and 2 (2/7) in PR status and 3 (3/7) in progression disease (PD) status before transplantation in allo-HSCT group. The median follow-up for the surviving patients was 46.5 months (range, 1-100 months) for the whole series, two patients lost in auto-HSCT group. Three patients developed acute graft-versus-host disease (aGVHD) and 5 chronic graft-versus-host disease (cGVHD) after allo-HSCT. Three patients died of primary disease and 1bleeding in auto-HSCT group. One patient died of primary disease and 2 transplantation-related mortality in allo-HSCT group. The 3-year cumulative overall survival (OS) were 56% (95%CI 32%-100%) and 57% (95%CI 30%-100%) for auto-HSCT and allo-HSCT, respectively (P=0.979) . The 3-year cumulative progression-free survival (PFS) were 34% (95%CI 14%-85%) and 57% (95%CI 30%-100%) for auto-HSCT and allo-HSCT, respectively (P=0.451) . Conclusion: Both auto-HSCT and allo-HSCT were optimal choices for AITL. In clinical practice, which HSCT was better for AITL patients should be based on comprehensive factors including sensitivity to chemotherapy, risk stratification and disease status at transplantation. 目的: 分析造血干细胞移植(HSCT)治疗血管免疫母细胞性T细胞淋巴瘤(AITL)的临床疗效。 方法: 回顾性分析2007年6月至2017年6月期间在国内八所医院接受HSCT的AITL患者。 结果: 共有19例患者纳入本研究,其中男13例,女6例,中位年龄50(32~60)岁;自体造血干细胞移植(auto-HSCT)12例,异基因造血干细胞移植(allo-HSCT)7例(均为同胞全相合供者,其中2例为auto-HSCT后复发患者)。auto-HSCT组移植前疾病处于完全缓解(CR)、部分缓解(PR)状态者分别为5例、7例;allo-HSCT组患者移植前疾病处于PR、疾病进展(PD)状态者分别为2例、3例。失访2例(均为auto-HSCT组),中位随访时间46.5(1~100)个月。allo-HSCT组3例患者发生急性移植物抗宿主病(GVHD)(Ⅰ度2例,Ⅱ度1例),5例发生慢性GVHD(局限型2例,广泛型3例)。auto-HSCT组死亡4例(原发病复发死亡3例),allo-HSCT组死亡3例(移植相关死亡2例,原发病复发死亡1例)。auto-HSCT组(10例)、allo-HSCT组(7例)的3年总生存率分别为56%(95%CI 32%~100%)、57%(95%CI 30%~100%)(P=0.979);3年累积无进展生存率分别为34%(95%CI 14%~85%)、57%(95%CI 30%~100%)(P=0.451)。 结论: auto-HSCT和allo-HSCT均是AITL的有效治疗方法。.
引用
- Xu LM, Li NN, Wang Z, et al. [Clinical outcomes of hematopoietic stem cell transplantation for angioimmunoblastic T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32397020. doi:10.3760/cma.j.issn.0253-2727.2019.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。